Qi-Long-Tian capsule alleviates pulmonary fibrosis development by modulating inflammatory response and gut microbiota

Zhang, Qiang; Luo, Ting; Yuan, Dezheng; Liu, Jing; Yi, Fujin; Yuan, Jiali

doi:10.1007/s10142-023-00988-3

Cited by 6 publications

(8 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have found that inflammation and oxidative stress also play an important role in the development of pulmonary fibrosis ( Cameli et al, 2020 ; Q; Zhang et al, 2023 ). Hence, to evaluate the anti-inflammatory and antioxidant effects of Tan, we measured inflammation and oxidative stress-related indicators in mice lung tissues.…”

Section: Resultsmentioning

confidence: 99%

Tangeretin attenuates bleomycin-induced pulmonary fibrosis by inhibiting epithelial-mesenchymal transition via the PI3K/Akt pathway

Li,

Wei,

Song

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Pulmonary fibrosis (PF) is a terminal pathological change in a variety of lung diseases characterized by excessive deposition of extracellular matrix, for which effective treatment is lacking. Tangeretin (Tan), a flavonoid derived from citrus, has been shown to have a wide range of pharmacological effects. This study aimed to investigate the role and potential mechanisms of Tan on pulmonary fibrosis.Methods: A model of pulmonary fibrosis was established by administering bleomycin through tracheal drip, followed by administering Tan or pirfenidone through gavage. HE and Masson staining were employed to assess the extent of pulmonary fibrosis. Subsequently, Western blot, enzyme-linked immunosorbent assay (ELISA), RNA sequencing, and immunohistochemistry techniques were employed to uncover the protective mechanism of Tan in PF mice. Furthermore, A549 cells were stimulated with TGF-β1 to induce epithelial-mesenchymal transition (EMT) and demonstrate the effectiveness of Tan in mitigating PF.Results: Tan significantly ameliorated bleomycin-induced pulmonary fibrosis, improved fibrotic pathological changes, and collagen deposition in the lungs, and reduced lung inflammation and oxidative stress. The KEGG pathway enrichment analysis revealed a higher number of enriched genes in the PI3K/Akt pathway. Additionally, Tan can inhibit the EMT process related to pulmonary fibrosis.Conclusion: Taken together, the above research results indicate that Tan suppresses inflammation, oxidative stress, and EMT in BLM-induced pulmonary fibrosis via the PI3K/Akt pathway and is a potential agent for the treatment of pulmonary fibrosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Tangeretin attenuates bleomycin-induced pulmonary fibrosis by inhibiting epithelial-mesenchymal transition via the PI3K/Akt pathway

Li,

Wei,

Song

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Qi-Long-Tian (QLT) capsule is an herbal formulation that consists of San Qi, Di Long and Hong Jingtian. It was found to significantly increase the relative abundance of Bacteroidia and decrease the relative abundance of Clostridia, and intervene in PF by modulating the differential genera of intestinal flora, increasing the secretion of immunoglobulins, repairing the intestinal mucosal barrier, reducing the entry of LPS into the bloodstream, and decreasing the secretion of inflammatory factors in the serum ( Zhang et al., 2023 ).…”

Section: Treatmentmentioning

confidence: 99%

The mechanism of gut-lung axis in pulmonary fibrosis

Dong,

He,

Zhu

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Pulmonary fibrosis (PF) is a terminal change of a lung disease that is marked by damage to alveolar epithelial cells, abnormal proliferative transformation of fibroblasts, excessive deposition of extracellular matrix (ECM), and concomitant inflammatory damage. Its characteristics include short median survival, high mortality rate, and limited treatment effectiveness. More in-depth studies on the mechanisms of PF are needed to provide better treatment options. The idea of the gut-lung axis has emerged as a result of comprehensive investigations into the microbiome, metabolome, and immune system. This theory is based on the material basis of microorganisms and their metabolites, while the gut-lung circulatory system and the shared mucosal immune system act as the connectors that facilitate the interplay between the gastrointestinal and respiratory systems. The emergence of a new view of the gut-lung axis is complementary and cross-cutting to the study of the mechanisms involved in PF and provides new ideas for its treatment. This article reviews the mechanisms involved in PF, the gut-lung axis theory, and the correlation between the two. Exploring the gut-lung axis mechanism and treatments related to PF from the perspectives of microorganisms, microbial metabolites, and the immune system. The study of the gut-lung axis and PF is still in its early stages. This review systematically summarizes the mechanisms of PF related to the gut-lung axis, providing ideas for subsequent research and treatment of related mechanisms.

show abstract

“…A Qingwen Gupi decoction (QGT) is a mixture of Shengjiang powder and a Xiao Chaihu decoction, which can alleviate bleomycin-induced PF by reversing gut dysbiosis in a rat model [44]. A Qi-Long-Tian (QLT) capsule, consisting of San Qi (Notoginseng Radix et Rhizoma), Di Long (Pheretima aspergillum (E. Perrier)), and Hong Jingtian (Rhodiolae Crenulatae Radix et Rhizoma) [45], intervenes in PF by regulating the differential genera of the intestinal flora, repairing the intestinal mucosal barrier, reducing LPS entry into the blood, and decreasing inflammatory factor secretion in the serum [46]. Monomers derived from Chinese medicine have also been applied for the attenuation of PF.…”

Section: Traditional Chinese Medicinesmentioning

confidence: 99%

Regulation effect of the intestinal flora and intervention strategies targeting the intestinal flora in alleviation of pulmonary fibrosis development

GUO,

YANG

2024

Bioscience of Microbiota, Food and Health

View full text Add to dashboard Cite

Pulmonary fibrosis is an end-stage respiratory disease characterized by fibroblast proliferation and accumulation of extracellular matrix and collagen, which is accompanied by inflammatory damage. The disease is mainly based on pulmonary dysfunction and respiratory failure, the incidence of it is increasing year by year, and the current treatment methods for it are limited. In recent years, it has been found that gut microbes play a crucial role in the pathogenesis and development of pulmonary fibrosis. The microecological disturbance caused by changes in the composition of the intestinal flora can affect the course of pulmonary fibrosis. The regulatory network or information exchange system for gut-lung crosstalk is called the "gutlung axis". This review focuses on the frontier research on entero-pulmonary regulation in pulmonary fibrosis and on intervention strategies for changing the gut microbiota to improve pulmonary fibrosis, including fecal microbiota transplantation, traditional Chinese medicine interventions, and supplementation with probiotics. In addition, the present problems in this field are also raised in order to provide strong theoretical and strategic support for the future exploration of regulatory mechanisms and therapeutic drug development. This paper reviews the interaction of the intestinal flora with pulmonary fibrosis, introduces the research progress for improving pulmonary fibrosis through interventions targeted at the intestinal flora, and provides new ideas for the treatment of pulmonary fibrosis.

show abstract

Qi-Long-Tian capsule alleviates pulmonary fibrosis development by modulating inflammatory response and gut microbiota

Cited by 6 publications

References 61 publications

Tangeretin attenuates bleomycin-induced pulmonary fibrosis by inhibiting epithelial-mesenchymal transition via the PI3K/Akt pathway

Tangeretin attenuates bleomycin-induced pulmonary fibrosis by inhibiting epithelial-mesenchymal transition via the PI3K/Akt pathway

The mechanism of gut-lung axis in pulmonary fibrosis

Regulation effect of the intestinal flora and intervention strategies targeting the intestinal flora in alleviation of pulmonary fibrosis development

Contact Info

Product

Resources

About